Insurance Denied Multiple Sclerosis Treatment — Appeal Strategies

A multiple sclerosis diagnosis changes everything. You are managing unpredictable symptoms, adjusting to a new reality, and trying to stay ahead of a disease that can be relentless. Then your insurance company denies the treatment your neurologist prescribed — and that denial lands like another blow. You are not alone. MS patients face some of the highest rates of insurance denials in neurology, largely because disease-modifying therapies (DMTs) are expensive. But expensive is not the same as unnecessary. Here is how to fight back.

Why Insurers Deny MS Treatment

Insurance companies deny MS treatment for several recurring reasons:

• Step therapy (fail-first) requirements: Insurers demand you try cheaper medications before approving the one your neurologist prescribed — even when your doctor has clinical reasons to start with a specific drug.
• "Not medically necessary": The insurer questions whether your degree of disability or disease activity justifies the requested therapy.
• Off-label use: Some MS treatments are used for progressive forms of the disease where FDA approval language is narrow.
• Prior Authorization Denied: How to Appeal" class="auto-link">Prior authorization not submitted or denied: Many DMTs require pre-approval, and even small administrative errors can trigger denial.
• Formulary exclusion: Your prescribed drug is not on your plan's drug list, or requires a non-preferred tier exception.

Clinical Guidelines That Support Your Appeal

Your strongest weapons are published clinical standards. The American Academy of Neurology (AAN) has issued practice guidelines supporting early, aggressive treatment for MS, particularly for relapsing forms. Key arguments include:

• Early high-efficacy therapy (HET) is supported for patients at high risk of disability progression. Citing AAN's 2018 guidelines on DMT initiation strengthens the case that your doctor's choice is evidence-based.
• The National MS Society supports individualized treatment selection based on disease activity, lesion burden, and patient history — not a one-size-fits-all step therapy ladder.
• For progressive MS (primary or secondary), therapies like ocrelizumab (Ocrevus) and siponimod (Mayzent) have specific FDA indications that override "experimental" denials.

If your insurer is forcing step therapy, 35+ states have step therapy override laws requiring insurers to grant exceptions when a physician certifies that required step medications are contraindicated, previously failed, or would cause harm.

What to Include in Your Appeal Letter

Your appeal needs to be specific, clinical, and documented. Include:

1. Your neurologist's letter of medical necessity — asking them to specify your EDSS score, MRI lesion burden, relapse history, and why the denied therapy is the appropriate choice.
2. MRI reports showing disease activity or progression.
3. Documentation of prior treatment failures if step therapy is the issue.
4. Published clinical guidelines (AAN, National MS Society) supporting the requested treatment.
5. Your insurer's denial letter — address each stated reason directly.

State clearly that denial of effective DMT during periods of disease activity causes irreversible neurological damage. The cost of disability — wheelchairs, home care, lost wages — far exceeds the cost of treatment.

Demand an External Independent Review: Complete Guide" class="auto-link">External Review

If your internal appeal is denied, request an Independent Medical Review (IMR) or external appeal. By law, under the ACA, you have the right to have your case reviewed by an independent physician outside your insurance company. MS cases reviewed externally are overturned at high rates because the clinical evidence for DMTs is overwhelming.

You can also file a complaint with your state's Department of Insurance. If your plan is employer-sponsored (ERISA), contact your state insurance commissioner and consider consulting an attorney who handles ERISA claims.

Advocacy Organizations That Can Help

You do not have to navigate this alone:

• National MS Society (nationalmssociety.org) — has an insurance navigation team that helps patients appeal denials and find alternative funding
• Can Do MS (mscando.org) — wellness resources and peer support
• Patient Advocate Foundation (patientadvocate.org) — case managers who help navigate complex insurance situations
• Pharmaceutical manufacturer patient assistance programs — most DMT manufacturers (Biogen, Novartis, Roche/Genentech, Sanofi) offer free or reduced-cost drug programs if your appeal fails

If Your Treatment Is Time-Sensitive

If you are in the middle of a relapse or your neurologist has documented active lesions, request an urgent or expedited appeal. Under ACA rules, insurers must respond to expedited appeals within 72 hours for urgent situations. Document clearly why a delay causes harm — MRI evidence of active inflammation is compelling.

Fight Back With ClaimBack

Facing a denial when you are already living with MS is not just frustrating — it is potentially devastating to your long-term neurological health. ClaimBack helps MS patients build evidence-based, physician-supported appeal letters that address every specific denial reason with clinical precision.

Do not let an insurance company override your neurologist's judgment. Start your appeal today at https://claimback.app/appeal.

Related Reading

• How to Write an Insurance Appeal Letter
• What Is Medical Necessity?
• Internal vs. External Insurance Appeal — Know the Difference